Insulin glargine/insulin lispro - Adocia

Drug Profile

Insulin glargine/insulin lispro - Adocia

Alternative Names: BioChaperone Combo; BioChaperone glargine/lispro

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator Adocia
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 28 Sep 2016 The German regulatory agency approves the phase Ib trial for Type-2 diabetes mellitus (SC) before September 2016
  • 20 Sep 2016 Adocia and Profil initiate enrolment in a phase Ib trial in Type-2 diabetes mellitus (SC) in Germany
  • 03 May 2016 Adocia has patent protection for BioChaperone® Combo in Europe, USA, Mexico, China, Japan, Korea, Singapore, Russia, France, Australia, and South Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top